PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17506720-2 2007 ACE inhibitors currently approved for use in veterinary medicine are benazepril, enalapril, imidapril and ramipril. Enalapril 81-90 angiotensin I converting enzyme Canis lupus familiaris 0-3 26618728-7 2015 RESULTS: High doses of enalapril and benazepril caused significant reductions in serum ACE activity on all days but were not more effective than standard doses used in other studies. Enalapril 23-32 angiotensin I converting enzyme Canis lupus familiaris 87-90 26618728-9 2015 Serum aldosterone concentration also increased after drug administration, which mirrored changes in the UAldo:C. CONCLUSIONS AND CLINICAL RELEVANCE: In this study, administration of high doses of enalapril and benazepril significantly inhibited ACE activity, yet did not prevent increases in mean urine and serum aldosterone concentrations resulting from furosemide activation of RAAS. Enalapril 196-205 angiotensin I converting enzyme Canis lupus familiaris 245-248 25771846-2 2015 This study was designed to evaluate the efficacy of enalapril in suppressing ACE activity and furosemide-induced circulating RAAS activation. Enalapril 52-61 angiotensin I converting enzyme Canis lupus familiaris 77-80 25771846-4 2015 We hypothesized that enalapril would suppress ACE activity and furosemide-induced circulating RAAS activation. Enalapril 21-30 angiotensin I converting enzyme Canis lupus familiaris 46-49 25771846-8 2015 Enalapril inhibited ACE activity (P < 0.0001) but did not significantly reduce aldosterone excretion. Enalapril 0-9 angiotensin I converting enzyme Canis lupus familiaris 20-23 25771846-10 2015 Enalapril decreased plasma ACE activity; however, it did not suppress furosemide-induced RAAS activation, as determined by the UAldo:C. While enalapril blunts ACE activity, the absence of circulating RAAS suppression may be due to angiotensin II reactivation, alternative RAAS pathways, and furosemide overriding concurrent ACE inhibition, all indicating the existence of aldosterone breakthrough (ABT). Enalapril 0-9 angiotensin I converting enzyme Canis lupus familiaris 27-30 25771846-10 2015 Enalapril decreased plasma ACE activity; however, it did not suppress furosemide-induced RAAS activation, as determined by the UAldo:C. While enalapril blunts ACE activity, the absence of circulating RAAS suppression may be due to angiotensin II reactivation, alternative RAAS pathways, and furosemide overriding concurrent ACE inhibition, all indicating the existence of aldosterone breakthrough (ABT). Enalapril 142-151 angiotensin I converting enzyme Canis lupus familiaris 159-162 25771846-10 2015 Enalapril decreased plasma ACE activity; however, it did not suppress furosemide-induced RAAS activation, as determined by the UAldo:C. While enalapril blunts ACE activity, the absence of circulating RAAS suppression may be due to angiotensin II reactivation, alternative RAAS pathways, and furosemide overriding concurrent ACE inhibition, all indicating the existence of aldosterone breakthrough (ABT). Enalapril 142-151 angiotensin I converting enzyme Canis lupus familiaris 159-162 25771846-12 2015 The discrepancy between the current data and the documented benefits of enalapril likely reflects the efficacy of this ACE inhibitor in suppressing tissue RAAS, variable population responsiveness to ACE-inhibition, and/or providing additional survival benefits, possibly through as yet unknown mechanisms. Enalapril 72-81 angiotensin I converting enzyme Canis lupus familiaris 119-122 25771846-12 2015 The discrepancy between the current data and the documented benefits of enalapril likely reflects the efficacy of this ACE inhibitor in suppressing tissue RAAS, variable population responsiveness to ACE-inhibition, and/or providing additional survival benefits, possibly through as yet unknown mechanisms. Enalapril 72-81 angiotensin I converting enzyme Canis lupus familiaris 199-202 19732978-3 2011 The purpose of this study was to investigate the effects of the ACE inhibitor enalapril, the angiotensin-receptor blocker (ARB) irbesartan, and Ang-(1-7) on the chronic atrial ionic remodeling. Enalapril 78-87 angiotensin I converting enzyme Canis lupus familiaris 64-67 14613861-11 2003 ACE inhibition (enalapril) prevented increases in tissue angiotensin II concentration, phosphorylated ERK expression, Bax/Bcl-2 ratio, and cellular apoptosis, but did not affect total cell death, leukocyte infiltration, JNK or p38 activation, and reduced but did not eliminate tissue fibrosis. Enalapril 16-25 angiotensin I converting enzyme Canis lupus familiaris 0-3 12413500-1 2002 AIMS: The purpose of this study was to determine that the administration of an angiotensin converting enzyme (ACE) inhibitor enalapril would confer protection against doxorubicin-induced experimental heart failure, and attenuate the development of left ventricular dysfunction. Enalapril 125-134 angiotensin I converting enzyme Canis lupus familiaris 110-113 12661873-1 2003 OBJECTIVE: To determine whether the angiotensin converting enzyme inhibitor enalapril would lower systemic arterial and glomerular capillary pressure and reduce the magnitude of renal injury in a canine model of renal insufficiency. Enalapril 76-85 angiotensin I converting enzyme Canis lupus familiaris 36-65 10076917-7 1999 Enalapril increased plasma renin activity more strongly than did candesartan cilexetil, and significantly decreased vascular and plasma ACE activities. Enalapril 0-9 angiotensin I converting enzyme Canis lupus familiaris 136-139 10389851-9 1999 To assess whether this could be pharmacologically prevented, we administered enalapril to inhibit ACE during the 6 months of glucose intolerance to group 3. Enalapril 77-86 angiotensin I converting enzyme Canis lupus familiaris 98-101 11822810-1 2002 We evaluated the long-term effect of early angiotensin-converting enzyme (ACE) inhibition (enalapril maleate) as monotherapy to postpone or prevent congestive heart failure (CHF) in asymptomatic dogs with mitral regurgitation (MR) attributable to myxomatous valvular disease (MVD) in a prospective, randomized, double-blinded, placebo-controlled multicenter trial involving 14 centers in Scandinavia. Enalapril 91-108 angiotensin I converting enzyme Canis lupus familiaris 74-77 10076917-10 1999 The effect of the ACE inhibitor, enalapril, depended on the activity of ACE, whereas that of the Ang II receptor antagonist, candesartan, was independent of ACE activity. Enalapril 33-42 angiotensin I converting enzyme Canis lupus familiaris 18-21 10076917-10 1999 The effect of the ACE inhibitor, enalapril, depended on the activity of ACE, whereas that of the Ang II receptor antagonist, candesartan, was independent of ACE activity. Enalapril 33-42 angiotensin I converting enzyme Canis lupus familiaris 72-75 10076917-10 1999 The effect of the ACE inhibitor, enalapril, depended on the activity of ACE, whereas that of the Ang II receptor antagonist, candesartan, was independent of ACE activity. Enalapril 33-42 angiotensin I converting enzyme Canis lupus familiaris 72-75 8640982-4 1996 alone or in combination with the angiotensin-converting enzyme (ACE) inhibitor enalapril (0.1 mg/kg two times daily or 1 mg/kg). Enalapril 79-88 angiotensin I converting enzyme Canis lupus familiaris 64-67 9560765-6 1998 The value of AVE activity returned to normal by 24 hours for benazapril, whereas values for ACE activity remained below normal for enalapril, lisinopril, and ramipril at 24 hours. Enalapril 131-140 angiotensin I converting enzyme Canis lupus familiaris 92-95 9531670-0 1998 [Treatment of mitral valve insufficiency in dogs with the ACE inhibitor enalapril. Enalapril 72-81 angiotensin I converting enzyme Canis lupus familiaris 58-61 9531670-2 1998 The efficacy and safety of the angiotensin converting enzyme inhibitor enalapril in dogs with naturally acquired class III or class IV heart failure was evaluated in this study. Enalapril 71-80 angiotensin I converting enzyme Canis lupus familiaris 31-60 9374951-1 1997 OBJECTIVE: To compare the effects of the calcium channel blocker amlodipine with those of the angiotensin-converting enzyme (ACE) inhibitor enalapril on left ventricular (LV) remodelling and dysfunction during healing after reperfused anterior myocardial infarction (MI). Enalapril 140-149 angiotensin I converting enzyme Canis lupus familiaris 125-128 8569229-1 1995 We wished to elucidate the effects of the calcium-sensitizing positive inotropic agent MCI-154 and its combined use with an angiotensin-converting enzyme (ACE) inhibitor enalapril on postischemic contractile dysfunction. Enalapril 170-179 angiotensin I converting enzyme Canis lupus familiaris 124-153 12836713-2 1995 This study tested the hypothesis that treatment with the angiotensin-converting enzyme inhibitor enalapril prevents or delays the development of abnormalities of cardiopulmonary baroreflexes in dogs with LV dysfunction. Enalapril 97-106 angiotensin I converting enzyme Canis lupus familiaris 57-86 8569229-1 1995 We wished to elucidate the effects of the calcium-sensitizing positive inotropic agent MCI-154 and its combined use with an angiotensin-converting enzyme (ACE) inhibitor enalapril on postischemic contractile dysfunction. Enalapril 170-179 angiotensin I converting enzyme Canis lupus familiaris 155-158 2527528-13 1989 Following oral administration to conscious rats and intravenous administration to anaesthetised dogs, cilazapril was 2-4.5x more potent than enalapril as an ACE inhibitor. Enalapril 141-150 angiotensin I converting enzyme Canis lupus familiaris 157-160 7759729-2 1995 BACKGROUND: The beneficial effect of prolonged angiotensin-converting enzyme inhibitor therapy on remodeling during healing after myocardial infarction might be greater in anterior than inferior infarcts and more effective with captopril than enalapril therapy. Enalapril 243-252 angiotensin I converting enzyme Canis lupus familiaris 47-76 2314191-7 1990 Complete inhibition of ACE with enalapril (given at 3 mg/kg p.o., 3 hrs prior to cisplatin) reduced AII levels by 70%, but failed to significantly modify the increase in AVP levels (7.2 +/- 2.2 pg/ml), the latency time to emesis (149 +/- 2 min) and the number of emetic episodes induced by cisplatin. Enalapril 32-41 angiotensin I converting enzyme Canis lupus familiaris 23-26 7494555-4 1995 In the present study, we examined the effects of early, long-term monotherapy with the angiotensin converting enzyme (ACE) inhibitor, enalapril, on the progression of LV remodeling in dogs with LV dysfunction (ejection fractions 30-40%) produced by multiple sequential intracoronary microembolizations. Enalapril 134-143 angiotensin I converting enzyme Canis lupus familiaris 87-116 7494555-4 1995 In the present study, we examined the effects of early, long-term monotherapy with the angiotensin converting enzyme (ACE) inhibitor, enalapril, on the progression of LV remodeling in dogs with LV dysfunction (ejection fractions 30-40%) produced by multiple sequential intracoronary microembolizations. Enalapril 134-143 angiotensin I converting enzyme Canis lupus familiaris 118-121 8091887-5 1994 Specifically, enalapril during low-sodium diet elicited an exaggerated increase in PRA and a diminished decrease in ACE and ANP when compared to the results of the drug during normal-sodium diet. Enalapril 14-23 angiotensin I converting enzyme Canis lupus familiaris 116-119 1356560-4 1992 ACE-inhibition, with enalapril (2 mg kg-1), caused a significant reduction in systemic arterial blood pressure (BP) with little or no effect on cardiac function, and a significant elevation of plasma renin activity (PRA). Enalapril 21-30 angiotensin I converting enzyme Canis lupus familiaris 0-3 6089310-3 1984 The dogs were then subjected to ACE-inhibition with enalapril. Enalapril 52-61 angiotensin I converting enzyme Canis lupus familiaris 32-35 27786020-2 1984 The dogs were then subjected to ACE-inhibition with enalapril. Enalapril 52-61 angiotensin I converting enzyme Canis lupus familiaris 32-35 2849951-4 1988 Heart rate was found to be decreased from 62 +/- 7 min-1 to 58 +/- 7 min-1 after 1 h. The angiotensin converting enzyme (ACE)-inhibitor enalapril caused a complete reduction of the angiotensin induced hypertension. Enalapril 136-145 angiotensin I converting enzyme Canis lupus familiaris 90-119 2849951-4 1988 Heart rate was found to be decreased from 62 +/- 7 min-1 to 58 +/- 7 min-1 after 1 h. The angiotensin converting enzyme (ACE)-inhibitor enalapril caused a complete reduction of the angiotensin induced hypertension. Enalapril 136-145 angiotensin I converting enzyme Canis lupus familiaris 121-124 6124377-8 1982 A procedure was developed for the quantitation of MK-422 and enalapril in plasma and urine by their inhibition of purified ACE. Enalapril 61-70 angiotensin I converting enzyme Canis lupus familiaris 123-126 26596464-7 2016 Glucocorticoid treatment was discontinued, and the angiotensin-converting enzyme inhibitor enalapril was administrated as an antiproteinuric agent. Enalapril 91-100 angiotensin I converting enzyme Canis lupus familiaris 51-80